Cancer Cachexia Market Set for Strong Growth at 8.9% CAGR Over 2025-2034

Cancer Cachexia Market Set for Strong Growth at 8.9% CAGR Over 2025-2034 | DelveInsight

Author : John snow | Published On : 18 Mar 2026

The cancer cachexia market across the 7MM is poised for significant expansion, fueled by groundbreaking therapies like ponsegromab (PF-06946860), S-pindolol benzoate (ACM-001.1), and TCMCB07. Key drivers include a growing prevalence linked to an aging population, better cancer survival enabling more cachexia cases, rising high-risk cancers (e.g., lung, pancreatic), and improved diagnostics, all intensifying the need for better clinical solutions. DelveInsight's Cancer Cachexia Market Insights report offers deep insights into current treatments, emerging drugs, therapy market shares, and market sizing from 2020 to 2034 across the 7MM (United States, EU4 [Germany, France, Italy, Spain], UK, Japan).

DelveInsight estimates the 7MM cancer cachexia market at USD 475 million in 2024. The US dominated with ~58% of the 7MM market in 2024, outpacing EU4, UK, and Japan. Standard treatments (progestins, corticosteroids, TNF inhibitors) generated ~USD 470 million in 2024 but offer limited benefits, underscoring major unmet needs. Diagnosed prevalent cases reached ~1.4 million in 2024 across 7MM, projected to increase by 2034. Pioneers like Pfizer, Actimed Therapeutics, Endevica Bio, and AVEO Oncology (LG Chem) are pushing novel agents, with several launches anticipated soon. Pipeline stars include Ponsegromab (PF-06946860), S-pindolol benzoate (ACM-001.1; MT-102), TCMCB07, Rilogrotug (AV-380), and more. Ponsegromab (PF-06946860) could generate ~USD 425 million in 7MM sales by 2034.

Discover which therapies are expected to grab the major cancer cachexia treatment market share @ Cancer Cachexia Market Report

Cancer cachexia is a complex wasting syndrome in advanced cancer, marked by severe skeletal muscle and fat loss leading to weakness. Unlike simple malnutrition, it resists nutritional fixes due to systemic inflammation from cytokines produced by tumors and host cells. These disrupt metabolism, causing anorexia, insulin resistance, and catabolism—especially in pancreatic, lung, and head/neck cancers. Diagnosis lacks a single test, relying on tools like PG-SGA/MNA, CT/DXA/BIA imaging, handgrip tests, labs (low albumin, high CRP), and scores like mGPS or CASCO for staging and prognosis.

This section details historical/current patient pools and 2020–2034 forecasts for 7MM, drawing from studies and KOL insights. Segmentation covers total diagnosed prevalent cases, gender-specific cases, tumor type-specific cases, and age-specific cases. Progestins (e.g., MEGACE, medroxyprogesterone) boost appetite/weight, but studies show similar short-term gains vs. dexamethasone—with risks like thromboembolism (megestrol) or weakness/ulcers (dexamethasone). They lack long-term impact, spurring alternatives like nutrition support. In Japan, Ono's ADLUMIZ (Anamorelin) gained approval in 2021 for NSCLC/CRC cachexia. Cytokine blockers target TNF-α, IL-1/IL-6, IFN-γ, which drive multi-tissue wasting via synergistic effects.

To know more about cancer cachexia treatment guidelines, visit @ Cancer Cachexia Treatment Options

Ponsegromab (PF-06946860) by Pfizer, S-pindolol benzoate (ACM-001.1; MT-102) by Actimed Therapeutics, TCMCB07 by Endevica Bio, and Rilogrotug (AV-380) by AVEO Oncology (LG Chem) represent leading pipeline therapies.

Discover more about cancer cachexia drugs in development @ Cancer Cachexia Clinical Trials

The market is transforming with demand from late-stage cancer patients and few competitors. Emerging therapies promise to reshape treatment, boosted by better diagnosis and efficacy. Challenges include poor chemo response, high infection/survival risks (30%+ cancer deaths from cachexia), economic burdens, QOL impacts, pipeline setbacks, pricing/reimbursement hurdles, specialist shortages, undiagnosed cases, and low awareness—all potentially curbing growth.

Japan leads Asia’s industry-sponsored clinical pipeline in cancer cachexia, anchored by Ono’s approved anamorelin program and new biologic efforts like TSP‑101. South Korea participates through co-sponsorship partnerships in Phase II cachexia studies (ASCA101CC). Taiwanese companies currently do not sponsor Phase 1–3 cachexia trials, although oncology R&D is active. Ono Pharmaceutical Co., Ltd. (Japan) has Anamorelin (ONO‑7643/Adlumiz), a ghrelin receptor agonist, in Phase II/III trials (jRCT2080224663) and approved in Japan for NSCLC/CRC cachexia. Tensegrity Pharma (Japan) has TSP‑101, an anti-Fn14 monoclonal antibody, in Phase I. BMI Korea / Meta Fines (Korea) co-sponsor ASCA101CC, a Phase II therapy modulating metabolism and inflammation (NCT07168226).

Discover which therapies and companies are expected to lead the cancer cachexia treatment market @ Cancer Cachexia Market Report

DelveInsight’s “Cancer Cachexia– Epidemiology Forecast – 2034” report delivers an in-depth understanding of Cancer Cachexia historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The leading Cancer Cachexia Companies developing therapies include - Helsinn Healthcare/Ono Pharmaceutical, Pfizer, Actimed Therapeutics, Endevica Bio, AVEO Oncology (an LG Chem company), and others.

Cancer Cachexia - Pipeline Insight, 2026

DelveInsight’s, “Cancer Cachexia - Pipeline Insight, 2026” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Cancer Cachexia pipeline landscape. The leading Cancer Cachexia Companies developing therapies include - Helsinn Healthcare/Ono Pharmaceutical, Pfizer, Actimed Therapeutics, Endevica Bio, AVEO Oncology (an LG Chem company), and others.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: [email protected]

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com